BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Etter EL, Mei KC, Nguyen J. Delivering more for less: nanosized, minimal-carrier and pharmacoactive drug delivery systems. Adv Drug Deliv Rev 2021;179:113994. [PMID: 34619287 DOI: 10.1016/j.addr.2021.113994] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhao L, Huang C, Zheng R, Rao X, Kong R, Guan R, Chen Z, Yu X, Cheng H, Li S. Photodynamic amplified immune checkpoint-blockade therapy of self-delivery bioregulator via epigenetic reprogramming. Chemical Engineering Journal 2023;453:139729. [DOI: 10.1016/j.cej.2022.139729] [Reference Citation Analysis]
2 Yuan H, Zhou L, Qi Z, Zhang C, Wang C. Preparation of pH-responsive solanesol-based poly (glutamic acid) micellar carrier for doxorubicin delivery. Materials Today Communications 2022;33:104800. [DOI: 10.1016/j.mtcomm.2022.104800] [Reference Citation Analysis]
3 Yang W, Yue H, Lu G, Wang W, Deng Y, Ma G, Wei W. Advances in Delivering Oxidative Modulators for Disease Therapy. Research 2022;2022:1-24. [DOI: 10.34133/2022/9897464] [Reference Citation Analysis]
4 Venditto VJ, Sockolosky J, Nguyen J. Translational Drug Delivery: Time to be Frank for Future Success. Adv Drug Deliv Rev 2022;:114521. [PMID: 36030019 DOI: 10.1016/j.addr.2022.114521] [Reference Citation Analysis]
5 Wang W, Zhong Z, Huang Z, Fu F, Wang W, Wu L, Huang Y, Wu C, Pan X. Two different protein corona formation modes on Soluplus® nanomicelles. Colloids Surf B Biointerfaces 2022;218:112744. [PMID: 35932562 DOI: 10.1016/j.colsurfb.2022.112744] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Peyravian N, Sun E, Dikici E, Deo S, Daunert S, Toborek M. Opioid Antagonist Nanodrugs Successfully Attenuate the Severity of Ischemic Stroke. Mol Pharm 2022. [PMID: 35506882 DOI: 10.1021/acs.molpharmaceut.2c00079] [Reference Citation Analysis]
7 Kyu Shim M, Yang S, Sun IC, Kim K. Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery. Adv Drug Deliv Rev 2022;183:114177. [PMID: 35245568 DOI: 10.1016/j.addr.2022.114177] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 17.0] [Reference Citation Analysis]
8 Khan MA, Iqbal J, Ilyas M, Ayub AR, Zhu Y, Li H. Controlled supramolecular interaction to enhance the bioavailability of hesperetin to targeted cancer cells through graphyne: a comprehensive in silico study. RSC Adv 2022;12:6336-46. [PMID: 35424570 DOI: 10.1039/d1ra09112c] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]